To: The Honorable Joseph Biden  
President of the United States  
The Honorable Xavier Becerra  
Secretary of Health and Human Services  
The Honorable Nancy Pelosi  
Speaker  
The Honorable Kevin McCarthy  
House Republican Leader  
The Honorable Chuck Schumer  
Senate Majority Leader  
The Honorable Mitch McConnell  
Senate Republican Leader

Dear President Biden, Secretary Becerra, Speaker Pelosi, Majority Leader Schumer, Leader McCarthy, Leader McConnell, America’s Lawmakers, Patient Advocates, and Fellow Americans:

We lead, fund, and count on the many small biotechnology companies that develop medicines for diseases* that lack sufficient treatments and cause considerable suffering. The companies led by the executives among us employ 23,250 people in the US and collectively invest over $17.7 billion/year in search of breakthroughs. We are currently testing 407 new and potentially life changing drug candidates in clinical trials, some of which build upon foundational NIH-funded research led by the academic researchers among us. The investors among us work at firms managing over $185 billion of life science-focused capital that comes primarily from pension funds, families, universities, non-profits, and others who invest in drug development. Many of us are also patients and patient advocates, with loved ones who suffer from difficult diseases in need of better treatment options. We have dedicated ourselves to that effort.

Collectively we come together to defeat disease. Each drug in development is a complex, time consuming, and expensive scientific and medical undertaking. Most of the time we lose the battle. But we persist because the few projects that succeed will forever improve human health.

Our industry invests over $160 billion in R&D each year. In the past decade it has created vaccines and treatments for Covid-19, treatments for cystic fibrosis and sickle cell disease, and cures for several cancers and hepatitis C. These successes are just a few examples of the many significant advances we are driving. Our efforts are reducing the burden and threat of diseases across the USA and around the globe.

It has become clear that we must also help our lawmakers understand the basic economic framework that inspires companies and investors to take the financial risk required to create new medicines. Called to action by the justifiable outrage of patients who cannot afford their out-of-pocket costs, some lawmakers have misdiagnosed the problem. They believe drug companies charge too much for their products. In response, they are proposing to enact laws that not only fall short of making drugs affordable to all patients but also defund our efforts to create better ones.

To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State.

We update this letter with signatories periodically, so your name won’t show up right away.
The Right Goal

To be clear, we are concerned about the high and rising out-of-pocket costs that have made our medicines increasingly unaffordable to many patients. We, too, call for a solution to affordability. We don’t invent drugs to have them placed out of the reach of people who need them.

Insurance makes it possible for Americans to afford today’s medicines and collectively invest in tomorrow’s, as is captured in this short video. To solve the problem of affordability for patients, we must lower the amount that insurance plans can make patients pay out-of-pocket, redefining proper insurance by law, just as policymakers have appropriately outlawed discrimination on the basis of pre-existing conditions.

The Wrong Policy

Instead, Congress is considering allowing the government to dictate the price that a company may charge for a novel drug with the threat of ruining the company financially with a 95% tax should the company refuse to accept the government’s price.

Such draconian measures would immediately halt private funding of drug discovery and development. As an industry, we would no longer be able to infer what insurance plans might value and pay tomorrow from what they value and pay today, which is the premise of a market economy. Unpredictable government-dictated prices would supplant the current market-based framework that inspires biomedical R&D investment.

The investors among us would have to shift our investments toward areas still governed by markets, such as technology and consumer goods. Those companies with drug candidates in development would fail to raise more capital, making it pointless for them to spend existing dollars on ongoing research. The loss of hundreds of thousands of well-paying jobs would be swift, though it may take longer for the public to sense the loss of future treatments and cures.

Some may think NIH funding will be sufficient to fund continued R&D. The NIH is a crucial funder of the basic research that provides the ideas for what kinds of drugs might be possible.

Translating those ideas into actual medicines is almost entirely driven by the private sector and makes all that basic research worth funding in the first place. Some of us signing this letter are NIH funded academic researchers whose discoveries have had significant patient impact, and we affirm that the private sector has been and will continue to be essential for turning our ideas into medicines. The NIH and industry are parts of one whole ecosystem, not a replacement for one another.
What’s in a Word?

Successful negotiations result in market-based prices based on competing alternatives – this negotiation already takes place between drug manufacturers and insurance companies, resulting in an average 50% reduction from drugs’ list prices to their net prices.

True negotiation requires that both parties can walk away from the table. True negotiation is acceptable to all of us and spurs us to compete. True negotiation means that even if we don’t get to the market first, our second and third place drugs can still secure some market share by competing on price.

The proposed introduction of a 95% tax penalty would allow The Center for Medicare and Medicaid Services (CMS) to simply dictate any drug’s price. This is not true negotiation.

As proposed, the government would be able to keep a company from walking away from an unacceptably low price. This gives the American public the impression that they can have any drug that’s been invented for any price, however low. Overlooked in that bargain is that investors and companies will stop investing in new programs, and we’ll give up the medicines that haven’t been invented yet.

Congress may not intend to dictate the price for every drug. But dictating the price of drugs covered by Medicare would defund R&D for diseases of aging, including Alzheimer’s, osteoporosis, and cancer. Dictating prices for medicines priced above a certain threshold would defund R&D for rare diseases. Dictating prices for medicines that generate the most total revenue would defund R&D for our most difficult diseases, since those are the ones that require greater expected revenues to incentivize substantial R&D investment.

Dictating prices for drugs deemed less “valuable” to society sounds tempting, until one realizes that the math for estimating a drug’s value is so nascent, imprecise, and controversial that it’s easily biased to reflect the preferences of the practitioner. For example, a recent business plan competition demonstrated that not a single project would be fundable if future products could only be priced in accordance with the over-simplified math used in the UK and Canada. Furthermore, there is mounting evidence from health economics research that medicines offer greater societal value than is reflected by their prices.

Better Solutions

We already have a functioning mechanism to drive down drug prices: drugs go generic. Because drugs go generic, what America spends on drugs has remained at roughly 10% of healthcare spending for decades, yet we have so many more effective and safer medicines today than in the 1970s.
Hospitals, long-term care facilities, and medical procedures do not go generic; those costs have only been climbing. We can keep ourselves from having to rely as much on hospitals in the future by inventing better medicines, which will then go generic. Society saves money, and we all lead healthier lives.

Preserving market-based incentives for drug R&D is how we get the medicines to achieve this goal. Heart transplants were first performed in 1967 and climbed in price by over 2,000% to cost $1.4 million today. The heart failure drug amiloride helps avert the need for transplants and was approved in 1967; today it costs 26 cents/pill. We haven’t solved heart failure, but we’re working on it. So, there’s hope for the people who need better heart failure medicines, but that hope requires continued investment in R&D.

America, and specifically CMS, can still save on drugs without sacrificing future treatments, cures, and vaccines. Certain drugs do not go generic even after their patents have expired, and CMS could save money by solving that particular market failure. Doing so would not reduce R&D incentives. Members of industry and others have proposed a specific, actionable framework for how this could work.

Averting A Costly Error

It’s true that replacing market-based pricing with non-market government-dictated prices will reduce healthcare spending in the short run (the Congressional Budget Office, which helps lawmakers determine what legislation may cost or save the government, uses a 10-year timeframe). But without new medicines, this policy will condemn America to spend far more on managing diseases in hospitals and long-term care facilities for decades to come.

The worst part is that it will take a long time to realize that we’re not making progress like we used to. For example, antibiotic R&D has historically suffered from low investment incentives because the prices of antibiotics are so low. Today, we urgently need new antibiotics to combat the rise of resistant bacterial infections, but it will take years to remedy this gap in R&D even with proper incentives and funding. It’s hard to appreciate what we don’t have until we need it.

The advocates among us know this acutely, having worked with so many patients struggling to make it to the next breakthrough.

Where there are market failures, we should fix them. All drugs should go generic without undue delay. Americans should not suffer because their insurance burdens them with unaffordable out-of-pocket costs, whether they get their drugs through Medicare, their employer insurance, or on the public exchanges. Patients and policyholders should benefit from the savings insurers negotiate with drug companies, and drugs covered under Medicare Part B should be subject to the same competitive

To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
market forces as those covered by Part D. Lawmakers should focus on these important, achievable, and bipartisan reforms for the benefit of all Americans.

In the meantime, the term “negotiation” must not be redefined to encompass the government dictating a price under threat of financial ruin. Were such a law to pass, capital would be immediately redirected away from biomedical R&D, with an immediate effect on biotechnology jobs and longer-term harm to patients and our national budget and security.

Some observers of the drug development ecosystem who propose different theories and models of how it works might contradict us. But the executives and investors among us write not as observers of biotech’s economic framework but as its actual elements and conductors; capital and incentives flow through our funds and our companies like electricity through a circuit. It is evident to us that replacing true negotiation with dictated prices would defund R&D, like flipping off a light switch.

Sincerely,

Peter Kolchinsky, Aoife Brennan, Alex Karnal, Jeremy Levin, Laura Shawver, Daphne Zohar, and Signatories to this Statement, listed below*:

Peter Kolchinsky, PhD
RA Capital Management, LP
Boston, MA

Aoife Brennan, MB, BCh, BAO, MRCPI
Synlogic Therapeutics
Cambridge, MA

Alex Karnal
Braidwell Management
New York City, NY

Jeremy Levin, D.Phil, MB BChir
Ovid Therapeutics
New York City, NY

Laura Shawver, PhD
Silverback Therapeutics
Seattle, WA

Daphne Zohar
PureTech Health
Boston, MA
<table>
<thead>
<tr>
<th>Name</th>
<th>Company/Institution</th>
<th>City, State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Langer, ScD</td>
<td>MIT</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Paul Hastings</td>
<td>Nkarta Therapeutics</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Bob Nelsen</td>
<td>ARCH Venture</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Jean Francois Formela, MD</td>
<td>Atlas Venture</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>John Maragagone, PhD</td>
<td>Alnylam Pharmaceuticals</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Gunnar Esiason, MBA</td>
<td>Boomer Esiason Foundation</td>
<td>New York, New York</td>
</tr>
<tr>
<td>Ted W. Love, MD</td>
<td>Global Blood Therapeutics</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Brook Byers</td>
<td>Kleiner Perkins</td>
<td>Menlo Park, CA</td>
</tr>
<tr>
<td>Siddhartha Mukherjee, MD Dphil</td>
<td>Columbia University</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Arjun Goyal, MD</td>
<td>Vida Ventures</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Wendye Robbins</td>
<td>Blade Therapeutics</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Ron Cohen, MD</td>
<td>Acorda Therapeutics</td>
<td>Ardsley, NY</td>
</tr>
<tr>
<td>Corey S. Goodman, PhD</td>
<td>venBio Partners</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Mark Murcko, PhD</td>
<td>Dewpoint Therapeutics</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Kush M Parmar, MD PhD</td>
<td>5AM Ventures</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Akiko Iwasaki</td>
<td>Yale University</td>
<td>New Haven, CT</td>
</tr>
<tr>
<td>Nina Kjellson</td>
<td>Canaan Partners</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Rajeev Shah</td>
<td>RA Capital Management, LP</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>J. Tyler Martin, MD</td>
<td>Adjuvance Technologies</td>
<td>Lincoln, NE</td>
</tr>
<tr>
<td>Robert Ang</td>
<td>Vor BioPharma</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>D.A. Wallach</td>
<td>Time BioVentures</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>Jeffrey L Cleland, PhD</td>
<td>Ashvattha Therapeutics</td>
<td>Redwood City, CA</td>
</tr>
<tr>
<td>Jake Be克拉ft, PhD</td>
<td>Strand Therapeutics Inc</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Peter A. Thompson, MD</td>
<td>OrbiMed Advisors</td>
<td>New York, NY</td>
</tr>
<tr>
<td>James McArthur, PhD</td>
<td>PepGen Inc</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Robert D. Schultz</td>
<td>Satsuma Pharmaceuticals, Inc.</td>
<td>Durham, NC</td>
</tr>
<tr>
<td>Jeffrey Bird, MD, PhD</td>
<td>Bluebird Ventures</td>
<td>Palo Alto, California</td>
</tr>
<tr>
<td>Troy Wilson, PhD, JD</td>
<td>Kura Oncology</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>Peter Bisgaard</td>
<td>Pivotal Life Sciences</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>John A. Scarlett, MD</td>
<td>Geron Corporation</td>
<td>Foster City, CA</td>
</tr>
<tr>
<td>Todd Harris</td>
<td>Tyra Biosciences</td>
<td>Carlsbad, CA</td>
</tr>
<tr>
<td>Paul Bolno, MD</td>
<td>Wave Life Sciences</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Cedric Francois, MD, PhD</td>
<td>Apellis Pharmaceuticals, Inc.</td>
<td>Waltham, MA</td>
</tr>
<tr>
<td>Marc de Garidel</td>
<td>CinCor</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Andreas Wicki</td>
<td>HBM Healthcare Investments AG</td>
<td>Zug, Switzerland</td>
</tr>
<tr>
<td>Jill C. Milne, PhD</td>
<td>Catabasis Pharmaceuticals</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Jeffrey A. Leerink</td>
<td>SVB Leerink</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Jay Venkatesan, MD</td>
<td>Angion</td>
<td>Uniondale, NY</td>
</tr>
<tr>
<td>Nicholas Oo</td>
<td>Invus</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Stephen J. Hoffman, PhD, MD</td>
<td>Apic-Bio, Inc.</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>David A. Katz, PhD</td>
<td>Sparrow Pharmaceuticals</td>
<td>Portland, OR</td>
</tr>
<tr>
<td>Joseph Healey</td>
<td>HealthCor Management</td>
<td>New York, NY</td>
</tr>
</tbody>
</table>

To join us in signing this letter, [please click here](#) and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
<table>
<thead>
<tr>
<th>Name</th>
<th>Company</th>
<th>City, State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Resnick, MD</td>
<td>RA Capital</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Blake Wise</td>
<td>Novome Biotechnologies</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Ashley Dombkowski, PhD</td>
<td>Alladapt Immunotherapeutics, Inc</td>
<td>Menlo Park, CA</td>
</tr>
<tr>
<td>Michael R. Hayden, MBChB, PhD</td>
<td>Prilenia Therapeutics</td>
<td>Herszilya, Israel</td>
</tr>
<tr>
<td>Timothy M Shannon, MD</td>
<td>Canaan Partners</td>
<td>Westport, CT</td>
</tr>
<tr>
<td>Nancy A. Thornberry</td>
<td>Kallytpe</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Frank Watanabe</td>
<td>Arcutis Biotherapeutics</td>
<td>Westlake Village, CA</td>
</tr>
<tr>
<td>Ken Drazan</td>
<td>Arsenal Biosciences</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Jon Edwards, PhD</td>
<td>Red Tree Venture Capital</td>
<td>Menlo Park, CA</td>
</tr>
<tr>
<td>Yishai Zohar</td>
<td>Gelesis Inc</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Sadik H. Kassim, PhD</td>
<td>Vor Bio</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Eric Dube, PhD</td>
<td>Travere Therapeutics</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>Scott Clarke</td>
<td>Ambagon Therapeutics</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Stephen Dilly M.B.B.S., Ph.D</td>
<td>Sierra Oncology</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Jeff Albers</td>
<td>Blueprint Medicines</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>David-Alexandre C. Gros, MD</td>
<td>Eledon Pharmaceuticals</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>Alain D. Baron, MD</td>
<td>Escient Pharmaceuticals</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>Amit D. Munshi</td>
<td>Arena Pharmaceuticals Inc</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>John Kollins</td>
<td>Satsuma Pharmaceuticals, Inc.</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Amy Burroughs</td>
<td>Cleave Therapeutics</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Sarah Boyce</td>
<td>Avidity Bioscience</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>David Sable, MD</td>
<td>Special Situations Life Sciences Fund</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Sean Jeffries, PhD</td>
<td>Design Therapeutics</td>
<td>Carlsbad, CA</td>
</tr>
<tr>
<td>Dr. Vipin Garg</td>
<td>AlImmune, Inc.</td>
<td>Gaithersburg, MD</td>
</tr>
<tr>
<td>James A. Geraghty</td>
<td>Fulcrum Therapeutics</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Gregory J. Flesher</td>
<td>Reneo Pharmaceuticals, Inc.</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>Andy Schwab</td>
<td>5AM Ventures</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Cris Montero, PhD</td>
<td>RA Capital Management, LP</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Agustin Mohedas, PhD</td>
<td>Janus Henderson Investors</td>
<td>Denver, CO</td>
</tr>
<tr>
<td>Larry Feinberg</td>
<td>Oracle Partners L.P.</td>
<td>Greenwich, CT</td>
</tr>
<tr>
<td>Andrew N. Schiff, MD</td>
<td>Aisling Capital</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Melisssa McCracken, PhD</td>
<td>Nextech Invest</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Ed Mascioli</td>
<td>EMMDDL LC</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Alex Virgilio</td>
<td>Asymmetry Capital Management</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Brian Halak, PhD</td>
<td>Domain Associates</td>
<td>Princeton, NJ</td>
</tr>
<tr>
<td>Nassim Usman, PhD</td>
<td>Catalyst Biosciences</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Jak Knowles</td>
<td>Affini-T Therapeutics</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Dan Becker, MD, PhD</td>
<td>Access Biotechnology</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Doug Crawford</td>
<td>Mission BioCapital</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Matt Eckler</td>
<td>Arrowmark Partners</td>
<td>Denver, CO</td>
</tr>
<tr>
<td>Vikram Khanna</td>
<td>Ikarian Capital</td>
<td>Dallas, TX</td>
</tr>
<tr>
<td>Todd Foley</td>
<td>MPM Capital</td>
<td>Cambridge, MA</td>
</tr>
</tbody>
</table>
To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
H. Stewart Parker  
Parker BioConsulting  
Chapel Hill NC

John P. Butler  
Akebia Therapeutics  
Cambridge, MA

James N. Campbell, MD, FAANS  
Centrexion Therapeutics  
Baltimore, MD

Russell Cox  
Epirium Bio  
San Diego, CA

Erich Scheller, PhD  
RA Capital Management, LP  
Boston, MA

Joseph Edelman  
Perceptive Advisors  
New York, NY

Derek DiRocco, PhD  
RA Capital Management, LP  
Boston, MA

David H. Crean  
Coast BioVentures  
San Diego, CA

Matt Cohen, PhD  
Osage University Partners, LP  
Bala Cynwyd, PA

Jeremy P. Springhorn, PhD  
Nido Biosciences  
Cambridge, MA

Peter Strumph  
Parvus Therapeutics  
San Francisco, CA

Jon Soderstrom, PhD  
Yale University  
New Haven, CT

Tess Cameron  
RA Capital Management, LP  
Boston, MA

Scott M. Rocklage  
5AM Ventures  
Boston, MA

Kevin Kimberlin  
Spencer Trask & Co  
Greenwich, CT

Laura Stoppel, PhD  
RA Capital Management, LP  
Boston, MA

Scott Kellen  
DiaMedica Therapeutics Inc.  
Minneapolis, MN

Bassil Dahiyat  
Xencor  
Monrovia, CA

Pratik Shah, PhD  
Design Therapeutics  
San Diego, CA

Jason Gardner  
Magenta Therapeutics  
Cambridge, MA

Joshua T. Brumm  
Dyne Therapeutics  
Waltham, MA

Brad Loncar  
Loncar Investments  
Lenexa, KS

Armando Anido  
Zynerba Pharmaceuticals  
Devon, PA

Sandip Agarwala  
Longitude Capital  
Greenwich, CT

Dennis Purcell  
Aisling Capital  
New York City, NY

Walter H. Moos  
Pandect Bioventures  
South San Francisco, CA

Randy Mitchell  
Ayeska Investment Group  
Chicago, IL

Reza Halse, PhD  
RA Capital Management, LP  
Boston, MA

John Tucker  
scPharma  
Burlington, MA

Ronald C Renaud Jr.  
Translate Bio  
Lexington, MA

Adam Keeney  
NodThera  
Lexington, MA

Nancy Simonian  
Syros Pharmaceuticals  
Cambridge, MA

Randy Wilson  
Gurnet Point  
Cambridge MA

Jeremy Bender, PhD  
Day One Biopharmaceuticals, Inc.  
South San Francisco, CA

Kate Moreau, PhD  
RA Capital Management, LP  
Boston, MA

Jeff Kindler  
Centrexion Therapeutics  
Boston, MA

Jeffrey H. Knapp  
DNAtrix, Inc.  
Houston, TX

Mike Derkacz  
Braeburn  
Plymouth Meeting, PA

Jason Lin  
TwoThree Capital  
Toronto, ON

Richard W. Pascoe  
Histogen Inc.  
San Diego, CA

Douglas Ingram  
Sarepta Therapeutics  
Cambridge, MA

To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State.

We update this letter with signatories periodically, so your name won’t show up right away.

Catherine Pearce, DHSc, MBA
CinCor Pharma Inc.
Cincinnati, OH

Emily Drabant Conley, PhD
Federation Bio
South San Francisco, CA

Timothy P. Walbert
Horizon Therapeutics
Deerfield, IL

Justin R. Thompson
CinCor Pharma, Inc.
Cincinnati, OH

Steven Burke, MD
Akebia Therapeutics
Cambridge, MA

Stan Wang, MD, PhD
Thymmune Therapeutics
Cambridge, MA

Albert Seymour, PhD
Homology Medicines, Inc.
Bedford, MA

Richard Gaster, MD, PhD
venBio Partners
San Francisco, CA

Rohan Palekar
89bio Inc.
San Francisco, CA

Alyssa Larson, PhD
RA Capital Management, LP
Boston, MA

Daniel Bensen
Tyra Biosciences, Inc.
Carlsbad, CA

Nancy Lurker
EyePoint Pharmaceuticals
Watertown, MA

Neil Exter
Third Rock Ventures
Boston, MA

John L. LaMattina
PureTech Health
Stonington, CT

Ron Hunt
New Leaf Venture Partners
New York, NY

Chip Clark
Genocea Biosciences, Inc.
Cambridge, MA

Nathaniel Brooks Horwitz
RA Capital Management, LP
Boston, MA

Ivor Royston, MD
Viracta Therapeutics
Cardiff, CA

William E. Rote, PhD
Travere Therapeutics
San Diego, CA

Jason Rhodes
Atlas Venture
Boston, MA

Peter Parker
Mission BioCapital
Cambridge, MA

June H. Lee, MD
Esker Therapeutics
San Francisco, CA

Lee D. Cooper
Leaps by Bayer
Cambridge, MA

Todd Krueger
AOBiome Therapeutics
Cambridge, MA

Jonathan Piazza
Silverback Therapeutics
Seattle, WA

Otello Stampacchia
Omega Funds
Boston, MA

Paulina Hill
Omega Funds
Boston, MA

Cristina Ghenoiu, PhD
RA Capital Management, LP
Boston, MA

Ankit Mahadevia, MD
Spero Therapeutics
Cambridge, MA

Ari Zweiman
683 Capital Management LLC
New York, NY

Adrian Gottschalk
Foghorn Therapeutics
Cambridge, MA

Brian Rosenberger
Zymera Pharmaceuticals
Devon, PA

Mark Leuchtenberger
Aleta Biotherapeutics
Natick, MA

Will Brown
Altimmune, Inc.
Gaithersburg, Maryland

Kristina Burow
ARCH Venture Partners
Chicago, IL

Mike Sherman
Chimerix
Durham, North Carolina

Daniel E. Rosan
Synlogic Therapeutics
Cambridge, MA

Philip Astley-Sparke
Replimune Inc
Boston, MA

CJ Sylvester
Manulife
Boston, MA

Adrian (Ad) Rawcliffe
Adaptimmune
Philadelphia, PA

Faheem Hasnain
Gossamer Bio
San Diego, CA

Ephraim Heller
SynAgile Corporation
Wilson, WY
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>City, State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rebecca Lucia, CFA</td>
<td>5AM Ventures</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>W. Eddie Martucci, PhD</td>
<td>Akili Interactive Labs</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Fouad Azzam, PhD</td>
<td>Life Sciences Partners</td>
<td>Waltham, MA</td>
</tr>
<tr>
<td>Habib Dable</td>
<td>Acceleron Pharma</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>David V. Goeddel, PhD</td>
<td>Tenaya Therapeutics</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>Steven Gillis</td>
<td>ARCH Venture Partners</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Carl L. Hansen, PhD</td>
<td>AbCellera</td>
<td>Vancouver, BC Canada</td>
</tr>
<tr>
<td>Adam M. Koppel</td>
<td>Bain Capital Life Sciences</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Raju Kucherlapati</td>
<td>Harvard Medical School</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Jonathan Kipnis</td>
<td>Washington University in St. Louis</td>
<td>St. Louis, MO</td>
</tr>
<tr>
<td>Brian S. Kim, MD, MTR, FAAD</td>
<td>Washington University School of Medicine</td>
<td>St. Louis, MO</td>
</tr>
<tr>
<td>Norbert Bischofberger</td>
<td>Kronos Bio</td>
<td>San Mateo, CA</td>
</tr>
<tr>
<td>Angie You, PhD</td>
<td>Amunix Pharmaceuticals</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td>Kevin Bitterman</td>
<td>Atlas Venture</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Braeburn</td>
<td>Plymouth Meeting, PA</td>
</tr>
<tr>
<td>Mike Powell</td>
<td>Omega Funds</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Fred Asian, MD</td>
<td>Artiva Biosciences</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>Michael A. Schrader</td>
<td>Vaxess Technologies, Inc.</td>
<td>Cambridge, MA</td>
</tr>
<tr>
<td>David Grayzel, MD</td>
<td>Atlas Venture</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Kris Jenner</td>
<td>Rock Springs Capital</td>
<td>Baltimore, MD</td>
</tr>
<tr>
<td>David Kroin</td>
<td>Deep Track Capital</td>
<td>Greenwich, CT</td>
</tr>
<tr>
<td>Vicente Anido, PhD</td>
<td>Aerie Pharmaceuticals, Inc.</td>
<td>Durham, NC</td>
</tr>
<tr>
<td>Aaron Davis</td>
<td>Boxer Capital</td>
<td>San Diego, CA</td>
</tr>
<tr>
<td>Evan Loh, MD</td>
<td>Paratek Pharmaceuticals</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Stephen Hurly</td>
<td>LAVA Therapeutics</td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>Jerry Cahill</td>
<td>Boomer Esiason Foundation</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Dave Madden</td>
<td>River 2 and 3 Renal Corps</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Robert L. Hudkins</td>
<td>Tyra Bioscience</td>
<td>Carlsbad, CA</td>
</tr>
</tbody>
</table>

To join us in signing this letter, [please click here](#) and you'll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
Adam Muzikant, PhD
Flexion Therapeutics
Burlington, MA

Jose Ochoa
Altimmune
Gaithersburg, MD

Josh Richardson
Longitude Capital
Boston, MA

Emily Schaller
Rock CF Foundation
Detroit, MI

Lloyd M. Segal
Repave Therapeutics Inc.
Cambridge, MA

Kevin Pyun
Dellera Investments LP
Greenwich, CT

William S. Slattery
Deerfield Management
New York, NY

Ansbert Gadieke
MPM Capital
Cambridge, MA

Pascal Touchon
Atara Biotherapeutics
San Francisco, CA

Daniel Vitt
Immunic Therapeutics
New York City, NY

Robert Adelman, MD
venBio
San Francisco

Robert Blazej, PhD
MBC Biolabs
San Francisco, CA

Khrystal K Davis, JD
Texas Rare Alliance
Austin, TX

Michael Nolan
Freenome
South San Francisco, CA

Samuel L Murphy, PhD
Salubris Biotherapeutics
Cambridge, MA

Jim Sullivan, PhD
Vanqua Bio
Chicago, IL

Peter Wirth
Quan Capital Management
Boston, MA

Aaron Hakim, MD
Deep Track Capital
Boston, MA

Hillary Theakston
Clearity
San Diego, CA

Michelle Ho
5AM Ventures
San Francisco, CA

Mark Simon
Torreya Partners
New York, NY

Noah L. Rosenberg, MD
Travere Therapeutics
San Diego, CA

Bong Koh, MD
Venrock
New York, NY

James Brush, MD
Frazier Healthcare Partners
Menlo Park, CA

Galya Blachman
5AM Ventures
San Francisco, CA

Bruce Booth
Atlas Venture
Boston, MA

Thomas Malley
Mosrock Capital, LLC
Englewood, CO

Deborah Palestrant
5AM Ventures
Boston, MA

Albert Gianchetti
XyloCor Therapeutics
Malvern, PA

Douglas Fisher, MD
InterWest Partners
Menlo Park, CA

Barry Labinger
Checkmate Pharmaceuticals
Cambridge, MA

Peter Smith
Remix Therapeutics
Cambridge, MA

Daniel Koller
BB Biotech AG
Schaffhausen, Switzerland

Roderick Wong, MD
RTW Investments
New York, NY

John E. Osborn
BioVentures Investors
Wellesley, MA

Sanjiv Patel
Relay Therapeutics
Boston, MA

Vasudev Bailey, PhD
Artis Ventures
San Francisco

Sean McCarthy
CytomiX Therapeutics
South San Francisco, CA

Ryan Lane
Empere Asset Management LP
New York, NY

Chris Garabedian
Perceptive Advisors
Boston, MA

Jonathan Lim, MD
Erasca
San Diego, CA

Sandy Mong MD
Atlas Venture
Boston, MA

To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
James Blair  
Domain Associates LLC  
Princeton, NJ

Joanne Kotz, PhD  
Jnana Therapeutics  
Boston, MA

Allen Conger  
NeuroMedica  
Mt. Pleasant, SC

Michael Keyoung, MD, PhD  
CBC Group  
New York, NY

Seth Rotberg, MNM  
Our Odyssey  
Chicago, IL

Michael S. Weiss  
TG Therapeutics  
Boca Raton, FL

Bala Venkataraman  
Avego Management  
Alpharetta, GA

Stan Erck  
Novavax  
Gaithersburg, MD

Harris Weber  
Bain Capital  
Boston, MA

Gerard Smith  
Deep Track Capital  
Greenwich, CT

Michael Gladstone  
Atlas Venture  
Cambridge, MA

Axel Hoos  
Scorpion Therapeutics  
Boston, MA

Vincent S. Mosca  
Ditch Plains Capital Management  
Manhasset, NY

Colin Wang  
6 Dimensions Capital  
Cambridge, MA

Patrick Nosker, PhD  
Affinity Asset Advisors, LLC  
New York, NY

Fred Dotzler  
De Novo Ventures  
Saratoga, CA

Dan Janney  
Alta Partners  
Cambridge, MA

Michael J. Hearle  
Clough Capital Partners  
Boston, MA

Doug Roeder  
Delphi Ventures  
San Mateo, CA

David Allison  
5AM Ventures  
San Francisco, CA

Wende Hutton  
Canaan Partners  
Menlo Park CA

Robert F. Johnston  
Johnston Associates, Inc.  
South Hamilton, MA

Albert Cha  
Frazier Healthcare Partners  
Menlo Park, CA

Marc W. Elia  
M28 Capital Management  
Stamford, CT

Thomas A. Romero  
Capital Research Partners & Co.  
Norwalk, CT

Laurence Blumberg, MD  
Arch Oncology  
Brisbane, Ca

Bryan Roberts  
Venrock  
Palo Alto, CA

Jonathan Root, MD  
U.S. Venture Partners  
Menlo Park, CA

Gary Stern  
Eagle Health Investments  
Greenwich, CT

Lazar Dimitrov, PhD  
Day One Biopharmaceuticals  
South San Francisco, CA

Andrew Oberwager MD  
Machaan Capital Managmnt LP  
Stamford, CT

Benjamin Young  
Gray’s Creek Capital Partners  
Westport, CT

Julie Papanek Grant  
Canaan  
Menlo Park, CA

Owen Smith, MSc, CPFA  
4BIO Capital  
London, UK

Dr. Michael Fischer  
Medical Strategy - Investmentmanager  
Munich, Germany

Dmitry A. Kuzmin, PhD,FRSB  
4BIO Capital LLP  
London, U.K.

Matt Renna  
Westfield Capital Management  
Boston, MA

Thilo Schroeder  
Nextech Invest  
Zurich, CH

Torbjorn Bjerke, MD  
Arctic Asset Management  
Stockholm, Sweden

Nicole Vitullo  
Domain Associates, LLC  
Princeton, NJ

Chris Varma, PhD  
Frontier Medicines  
South San Francisco, CA

Francis Parnell, MD  
Parnell Pharmaceuticals Inc  
San Rafael, CA

To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
To join us in signing this letter, please click here and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.
* Diseases that companies affiliated with signatories are working to prevent, treat, or cure: ADHD, ALS, Alzheimer's, Amyloid diseases, Anemia, ARDS, Autism, Autoimmune Disorders, Benign Prostatic Hyperplasia, Blindness, Breast Cancer, Chemotherapy Induced Peripheral Neuropathy and Chemotherapy Induced Cognitive Impairment, Chronic Hepatitis B, Chronic Lymphocytic Leukemia, Chronic Pain, Cognitive Injuries, Colorectal Cancer, Complement Disorders, COVID, Dementia, DM1, DMD, Enteric Hyperoxaluria, Fragile X syndrome, FSGS, FSHD, Gout, Heart Failure, Huntington's Diseases, Idiopathic Pulmonary Fibrosis, IgA nephropathy, Infectious Disease, Inflammatory Bowel Disease, Influenza, Long COVID, Lung Cancer, Lupus, Major Depressive Disorder, Melanoma, MLD, MPS2, Multiple Sclerosis, NASH, NMOSD, Non-Hodgkin Lymphoma, Obesity, Opioid Use Disorder, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Parkinson's Psychosis, Pediatric Leukemias, Pediatric low grade glioma, PKU, Post-surgical Pain, Primary Biliary Cholangitis, Prostate Cancer, Pulmonary Arterial Hypertension, Rare Epilepsies, Renal Cancer, Retinal eye diseases, Rhett's Syndrome, Stroke, Type 1 Diabetes, Type 2 Diabetes, Uterine Cancer, and many other diseases.

**The appended signatures do not necessarily reflect the policy or position of any agency, organization, employer, or company with which the signatories are affiliated.

CC: House Energy and Commerce Committee Chair Pallone and Ranking Member McMorris Rodgers
    House Ways and Means Committee Chair Neal and Ranking Member Brady
    Senate Finance Chair Wyden and Ranking Member Crapo
    Senate Health, Education, Labor, and Pensions Chair Murray and Ranking Member Burr

To join us in signing this letter, [please click here](#) and you’ll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won’t show up right away.